Padsevonil is an innovative anti-seizure medication currently being studied for the treatment of drug-resistant epilepsy and focal-onset seizures. Designed as a novel therapeutic agent, it functions through… Read more
Padsevonil is an innovative anti-seizure medication currently being studied for the treatment of drug-resistant epilepsy and focal-onset seizures. Designed as a novel therapeutic agent, it functions through a unique mechanism by interacting with synaptic vesicle protein 2 (SV2) isoforms and acting as a partial agonist at the benzodiazepine site of GABAA receptors. Our collection provides essential reference standards for Padsevonil, including high-quality samples of the active pharmaceutical ingredient, its pharmacopeial and non-pharmacopeial impurities, and relevant metabolites. These compounds are critical for analytical testing, impurity profiling, and method validation during pharmaceutical development and regulatory quality control. Researchers also utilize our stable isotope labelled compounds to ensure precise quantification and accuracy in complex pharmacokinetic and metabolic studies. Each product supports the rigorous requirements of pharmaceutical laboratories dedicated to advancing treatments for neurological disorders.